This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to see if adding a medicine called CellCept (also called mycophenolate mofetil) to Gleevec (also called imatinib mesylate or ST1571) for patients with chronic myelogenous leukemia (CML) will make levels of an abnormal protein named BCR-ABL decrease to a greater extent than would happen with Gleevec by itself. The study will also try to see if doing so makes patients less likely to have problems from their leukemia like relapses if in remission or progression to more advanced and dangerous phases of CML. Finally, the study will examine whether another protein called LYN kinase is abnormally high and whether its levels go down with the combination of imatinib and mycophenolate.
Showing the most recent 10 out of 782 publications
